Mr. David Regan reports

SONA NANOTECH APPOINTS SEASONED BIOTECH COMMERCIAL EXECUTIVE MICHAEL A. FLEMING TO BOARD OF DIRECTORS

Sona Nanotech Inc. has appointed Michael A. Fleming to the board of directors of the company.

Mr. Fleming served as executive vice-president for commercial operations and subsequently as chief strategy officer of Coherus BioSciences. During his tenure with Coherus, he led the company's transformation from a development-stage organization into a commercial oncology business, architecting the commercial strategy and launch of Udenyca (pegfilgrastim-cbqv), Coherus's first oncology asset and a market-leading pegfilgrastim brand.

Earlier in his career, Mr. Fleming held senior leadership roles at Elan, Genentech and GlaxoSmithKline, where he directed global commercial strategy across multibillion-dollar franchises and led numerous product launches across oncology, infectious disease, metabolic and specialty therapeutics.

Mark Lievonen, chair of Sona Nanotech commented: "We are delighted to welcome Michael as a director to the company. Sona will benefit from Michael's significant biotech business experience built over a 35-year career guiding emerging life science companies through critical value inflection points including capital formation, clinical development and strategic transactions. His direct experience with immune-oncology assets and the relationships he brings will be valuable."

Michael Fleming commented: "I am delighted to join Sona at this exciting time as it builds on its recent, positive first-in-man clinical experience. Sona's targeted hyperthermia therapy is a compelling potential treatment at a time when oncology is moving toward modulating the tumour microenvironment to engage the immune system in a less toxic way. I look forward to working with the board and management as Sona translates its gold nanorod platform into a therapeutics business."

About Sona Nanotech Inc.

Sona Nanotech is developing Targeted Hyperthermia, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat.

We seek Safe Harbor.